Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALIREZA NAMI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1851312755
CMS profile
83543
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,182.75

73 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $2,040.00 1
Food and Beverage $1,142.75 72

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALIREZA NAMI

NPI 1851312755 · CMS profile ID 83543

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1851312755?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALIREZA NAMI, NPI 1851312755, CMS profile ID 83543. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851312755?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ALIREZA NAMI, NPI 1851312755, CMS profile ID 83543. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851312755?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ALIREZA NAMI, NPI 1851312755, CMS profile ID 83543, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–73 of 73 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1851312755?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

73 matching records · $3,182.75 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 73 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–73 of 73.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $16.2404/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825125981 CMS
GlaxoSmithKline, LLC. $15.3704/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802886751 CMS
Amgen Inc. $6.5404/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825125973 CMS
PFIZER INC. $35.3504/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832591327 CMS
Amgen Inc. $21.4004/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825125933 CMS
E.R. Squibb & Sons, L.L.C. $19.4003/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783658825 CMS
Amgen Inc. $8.9503/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825125977 CMS
Horizon Therapeutics plc $14.8303/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797177955 CMS
Amgen Inc. $18.8603/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825125969 CMS
PFIZER INC. $26.6502/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832741337 CMS
Amgen Inc. $22.9502/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825125929 CMS
Janssen Biotech, Inc. $16.6702/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788746857 CMS
Amgen Inc. $4.9502/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825125965 CMS
UCB, Inc. $16.4502/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807315897 CMS
UCB, Inc. $15.9202/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807313135 CMS
Amgen Inc. $23.7002/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825125985 CMS
Janssen Biotech, Inc. $24.2702/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788746855 CMS
Lilly USA, LLC $14.2802/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818923447 CMS
Antares Pharma, Inc. $21.3402/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827499977 CMS
Amgen Inc. $19.0601/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825125897 CMS
Amgen Inc. $7.1701/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825125961 CMS
Amgen Inc. $24.2901/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825125953 CMS
Amgen Inc. $9.2201/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825125957 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $25,753.09 225
PY2020 $7,247.34 104
PY2021 $3,182.75 73
PY2022 $1,138.67 57
PY2023 $2,373.59 51
PY2024 $652.16 32
PY2025 $5,091.43 53

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $474,210.48 105
PY2024 Principal investigator $308,619.96 127
PY2023 Principal investigator $191,462.13 65
PY2022 Principal investigator $289,682.81 100
PY2021 Recipient $1,147.70 1
PY2021 Principal investigator $366,573.61 53
PY2020 Recipient $2,890.71 11
PY2020 Principal investigator $824,267.13 97
PY2019 Recipient $84.20 1
PY2019 Principal investigator $577,168.25 71

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

105 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $11,871.00 12/15/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175344306
Principal investigator 1 Janssen Research & Development, LLC $20,526.00 12/15/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175344336
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,504.40 12/10/2025 Non-covered Recipient Entity
Joint And Muscle Research Institute
Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus No dispute reported 06/30/2026 1235996423
Principal investigator 1 ABBVIE INC. $3,176.50 12/04/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202528184
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,426.93 11/19/2025 Non-covered Recipient Entity
Joint and Muscle Research Institute
INSPIRE LTE study No dispute reported 06/30/2026 1246432997
Principal investigator 1 Daiichi Sankyo Company LTD $3,306.00 11/07/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1186252391
Principal investigator 1 Daiichi Sankyo Inc. $1,500.00 11/07/2025 Covered Recipient Teaching Hospital
Carolinas Medical Center
DS7011-107 No dispute reported 06/30/2026 1223344459
Principal investigator 1 Daiichi Sankyo Inc. $1,806.00 11/07/2025 Covered Recipient Teaching Hospital
Carolinas Medical Center
DS7011-107 No dispute reported 06/30/2026 1223344461
Principal investigator 1 ABBVIE INC. $4,321.70 11/05/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202523053
Principal investigator 1 ABBVIE INC. $2,500.00 11/03/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202520033
Principal investigator 1 Janssen Research & Development, LLC $5,184.00 11/03/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175344282
Principal investigator 1 Janssen Research & Development, LLC $6,308.00 10/31/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175344290
Principal investigator 1 ABBVIE INC. $229.27 10/23/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202518407
Principal investigator 1 ABBVIE INC. $3,126.50 10/16/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202517317
Principal investigator 1 ABBVIE INC. $3,126.50 10/16/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202517319
Principal investigator 1 ABBVIE INC. $16,320.00 10/14/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202516721
Principal investigator 1 ABBVIE INC. $7,158.90 10/09/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202516085
Principal investigator 1 ABBVIE INC. $3,741.99 10/09/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202516087
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,366.87 10/08/2025 Non-covered Recipient Entity
Joint and Muscle Research Institute
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246433006
Principal investigator 1 Janssen Research & Development, LLC $9,789.00 10/06/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175344258
Principal investigator 1 Janssen Research & Development, LLC $9,266.00 10/06/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175344355
Principal investigator 1 Daiichi Sankyo Inc. $1.24 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370212
Principal investigator 1 Daiichi Sankyo Inc. $3.10 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370214
Principal investigator 1 Daiichi Sankyo Inc. $2.48 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370216
Principal investigator 1 Daiichi Sankyo Inc. $2.72 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370218
Principal investigator 1 Daiichi Sankyo Inc. $2.72 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370220
Principal investigator 1 Daiichi Sankyo Inc. $1.24 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370222
Principal investigator 1 Daiichi Sankyo Inc. $1.86 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370224
Principal investigator 1 Daiichi Sankyo Inc. $2.04 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370226
Principal investigator 1 Daiichi Sankyo Inc. $1.36 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370228
Principal investigator 1 Daiichi Sankyo Inc. $1.36 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370230
Principal investigator 1 Daiichi Sankyo Inc. $0.93 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370232
Principal investigator 1 Daiichi Sankyo Inc. $2.48 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370234
Principal investigator 1 Daiichi Sankyo Inc. $1.02 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370236
Principal investigator 1 Daiichi Sankyo Inc. $1.24 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370238
Principal investigator 1 Daiichi Sankyo Inc. $1.24 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370240
Principal investigator 1 Daiichi Sankyo Inc. $1.02 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370242
Principal investigator 1 Daiichi Sankyo Inc. $1.24 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370244
Principal investigator 1 Daiichi Sankyo Inc. $2.72 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370246
Principal investigator 1 Daiichi Sankyo Inc. $16.00 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370248
Principal investigator 1 Daiichi Sankyo Inc. $2.48 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370250
Principal investigator 1 Daiichi Sankyo Inc. $3.40 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370252
Principal investigator 1 Daiichi Sankyo Inc. $0.93 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370254
Principal investigator 1 Daiichi Sankyo Inc. $1.24 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370256
Principal investigator 1 Daiichi Sankyo Inc. $1.36 10/01/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370258
Principal investigator 1 ABBVIE INC. $12,674.00 09/04/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202509368
Principal investigator 1 Janssen Research & Development, LLC $7,732.00 08/28/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175344265
Principal investigator 1 Janssen Research & Development, LLC $4,678.00 08/28/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175344363
Principal investigator 1 ABBVIE INC. $3,365.00 08/06/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202502486
Principal investigator 1 ABBVIE INC. $1,408.38 08/05/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202501292
Principal investigator 1 Janssen Research & Development, LLC $4,253.00 07/31/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175344323
Principal investigator 1 Janssen Research & Development, LLC $11,459.00 07/31/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175344329
Principal investigator 1 Janssen Research & Development, LLC $17,448.00 07/07/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175344296
Principal investigator 1 Janssen Research & Development, LLC $23,177.00 07/07/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-nave Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175344369
Principal investigator 1 ABBVIE INC. $12,688.80 07/02/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202496081
Principal investigator 1 ABBVIE INC. $3,974.49 07/02/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202496083
Principal investigator 1 ABBVIE INC. $4,392.70 07/02/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202496085
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $865.80 06/25/2025 Non-covered Recipient Entity
Joint and Muscle Research Institute
INSPIRE LTE study No dispute reported 06/30/2026 1246432994
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $116.28 06/10/2025 Non-covered Recipient Entity
Joint and Muscle Research Institute
INSPIRE LTE study No dispute reported 06/30/2026 1246433014
Principal investigator 1 Janssen Research & Development, LLC $1,864.00 05/26/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175344313
Principal investigator 1 Daiichi Sankyo Company LTD $3,176.20 05/09/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1186252385
Principal investigator 1 Daiichi Sankyo Inc. $912.00 05/09/2025 Covered Recipient Teaching Hospital
Carolinas Medical Center
DS7011-107 No dispute reported 06/30/2026 1223344443
Principal investigator 1 Daiichi Sankyo Inc. $1,156.20 05/09/2025 Covered Recipient Teaching Hospital
Carolinas Medical Center
DS7011-107 No dispute reported 06/30/2026 1223344445
Principal investigator 1 Daiichi Sankyo Inc. $554.00 05/09/2025 Covered Recipient Teaching Hospital
Carolinas Medical Center
DS7011-107 No dispute reported 06/30/2026 1223344447
Principal investigator 1 Daiichi Sankyo Inc. $554.00 05/09/2025 Covered Recipient Teaching Hospital
Carolinas Medical Center
DS7011-107 No dispute reported 06/30/2026 1223344449
Principal investigator 1 Janssen Research & Development, LLC $18,028.00 05/09/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175344273
Principal investigator 1 ABBVIE INC. $8,128.00 05/07/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202482679
Principal investigator 1 ABBVIE INC. $3,628.86 05/06/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202481363
Principal investigator 1 Genentech, Inc. $3,427.00 04/28/2025 Non-covered Recipient Entity
JOINT + MUSCLE RESEARCH INSTITUTE
Study to investigate safety and efficiacy of Obinutuzumab in Patients with SLE No dispute reported 06/30/2026 1211619066
Principal investigator 1 ABBVIE INC. $6,375.00 04/23/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202478647
Principal investigator 1 Daiichi Sankyo Company LTD $11,752.20 04/09/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1186252389
Principal investigator 1 Daiichi Sankyo Inc. $3,105.00 04/09/2025 Covered Recipient Teaching Hospital
Carolinas Medical Center
DS7011-107 No dispute reported 06/30/2026 1223344451
Principal investigator 1 Daiichi Sankyo Inc. $3,105.00 04/09/2025 Covered Recipient Teaching Hospital
Carolinas Medical Center
DS7011-107 No dispute reported 06/30/2026 1223344453
Principal investigator 1 Daiichi Sankyo Inc. $3,424.00 04/09/2025 Covered Recipient Teaching Hospital
Carolinas Medical Center
DS7011-107 No dispute reported 06/30/2026 1223344455
Principal investigator 1 Daiichi Sankyo Inc. $2,118.20 04/09/2025 Covered Recipient Teaching Hospital
Carolinas Medical Center
DS7011-107 No dispute reported 06/30/2026 1223344457
Principal investigator 1 Janssen Research & Development, LLC $5,114.00 04/07/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175344346
Principal investigator 1 ABBVIE INC. $345.63 04/03/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202471761
Principal investigator 1 ABBVIE INC. $8,100.00 03/07/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202460609
Principal investigator 1 ABBVIE INC. $1,408.38 03/06/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202457723
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,036.97 03/03/2025 Non-covered Recipient Entity
Joint and Muscle Research Institute
INSPIRE LTE study No dispute reported 06/30/2026 1246433001
Principal investigator 1 ABBVIE INC. $3,974.49 02/05/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202445463
Principal investigator 1 ABBVIE INC. $3,556.80 02/04/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202443818
Principal investigator 1 ABBVIE INC. $1,382.52 02/04/2025 Non-covered Recipient Entity
JOINT AND MUSCLE RESEARCH INSTITUTE
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202443822
Principal investigator 1 Genentech, Inc. $29,441.00 01/22/2025 Non-covered Recipient Entity
JOINT + MUSCLE RESEARCH INSTITUTE
Study to investigate safety and efficiacy of Obinutuzumab in Patients with SLE No dispute reported 06/30/2026 1211619062
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,263.19 01/21/2025 Non-covered Recipient Entity
Joint And Muscle Medical Care
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) No dispute reported 06/30/2026 1235996425
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $116.28 01/20/2025 Non-covered Recipient Entity
Joint and Muscle Research Institute
INSPIRE LTE study No dispute reported 06/30/2026 1246433010
Principal investigator 1 Daiichi Sankyo Company LTD $6,483.60 01/15/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1186252387
Principal investigator 1 Daiichi Sankyo Inc. $2,881.60 01/15/2025 Covered Recipient Teaching Hospital
Carolinas Medical Center
DS7011-107 No dispute reported 06/30/2026 1223344465
Principal investigator 1 Daiichi Sankyo Inc. $3,602.00 01/15/2025 Covered Recipient Teaching Hospital
Carolinas Medical Center
DS7011-107 No dispute reported 06/30/2026 1223344467
Principal investigator 1 AstraZeneca UK Limited $100,711.45 01/08/2025 Non-covered Recipient Entity
JOINT AND MUSCLE MEDICAL CARE, PC
A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus No dispute reported 06/30/2026 1185544869
Principal investigator 1 Daiichi Sankyo Inc. $46.08 01/02/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370182
Principal investigator 1 Daiichi Sankyo Inc. $49.92 01/02/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370184
Principal investigator 1 Daiichi Sankyo Inc. $15.60 01/02/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370186
Principal investigator 1 Daiichi Sankyo Inc. $0.80 01/02/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370188
Principal investigator 1 Daiichi Sankyo Inc. $185.20 01/02/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370190
Principal investigator 1 Daiichi Sankyo Inc. $3.60 01/02/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370192
Principal investigator 1 Daiichi Sankyo Inc. $0.80 01/02/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370194
Principal investigator 1 Daiichi Sankyo Inc. $46.80 01/02/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370196
Principal investigator 1 Daiichi Sankyo Inc. $0.80 01/02/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370198
Principal investigator 1 Daiichi Sankyo Inc. $46.80 01/02/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370200
Principal investigator 1 Daiichi Sankyo Inc. $1.16 01/02/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370202
Principal investigator 1 Daiichi Sankyo Inc. $46.80 01/02/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370204
Principal investigator 1 Daiichi Sankyo Inc. $144.00 01/02/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370206
Principal investigator 1 Daiichi Sankyo Inc. $1.20 01/02/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370208
Principal investigator 1 Daiichi Sankyo Inc. $49.92 01/02/2025 Non-covered Recipient Entity
Joint & Muscle Research Institute
DS7011-107 No dispute reported 06/30/2026 1223370210